{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:03Z","timestamp":1792791483569,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["435002027"],"award-info":[{"award-number":["435002027"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["435002027"],"award-info":[{"award-number":["435002027"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["435002027"],"award-info":[{"award-number":["435002027"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Virgo consortium funded by the Dutch government"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The HIV-human metabolic relationship is a complex interaction convoluted even more by antiretroviral therapy (cART) and comorbidities. The ability of cART to undo the HIV induced metabolic dysregulation is unclear and under-investigated. Using targeted metabolomics and multiplex immune biomarker analysis, we characterized plasma samples obtained from 18 untreated HIV-1-infected adult patients and compared these to a non-HIV infected (n\u2009=\u200923) control population. The biogenic amine perturbations during an untreated HIV infection implicated altered tryptophan- nitrogen- and muscle metabolism. Furthermore, the lipid profiles of untreated patients were also significantly altered compared to controls. In untreated HIV infection, the sphingomyelins and phospholipids correlated negatively to markers of infection IP-10 and sIL-2R whereas a strong association was found between triglycerides and MCP-1. In a second cohort, we characterized plasma samples obtained from 28 HIV-1-infected adult patients before and 12 months after the start of cART, to investigate the immune-metabolic changes associated with cART. The identified altered immune-metabolic pathways of an untreated HIV infection showed minimal change after 12 months of cART. In conclusion, 12 months of cART impacts only mildly on the metabolic dysregulation underlying an untreated HIV infection and provide insights into the comorbidities present in virally suppressed HIV patients.<\/jats:p>","DOI":"10.1038\/s41598-018-35271-0","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T14:33:02Z","timestamp":1542033182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Persistent metabolic changes in HIV-infected patients during the first year of combination antiretroviral therapy"],"prefix":"10.1038","volume":"8","author":[{"given":"N. Chantal","family":"Peltenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-2467","authenticated-orcid":false,"given":"Johannes C.","family":"Schoeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-4295","authenticated-orcid":false,"given":"Amy C.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn H.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rgen","family":"Bierau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-7361","authenticated-orcid":false,"given":"Jaap A.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hankemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"35271_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-203","volume":"13","author":"E Cassol","year":"2013","unstructured":"Cassol, E. et al. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 13, 203 (2013).","journal-title":"BMC Infect Dis"},{"key":"35271_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/omi.2011.0035","volume":"17","author":"MA Ghannoum","year":"2013","unstructured":"Ghannoum, M. A. et al. Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: toward novel diagnostic targets. OMICS 17, 5\u201315 (2013).","journal-title":"OMICS"},{"key":"35271_CR3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/clinchem\/40.5.785","volume":"40","author":"GL Hortin","year":"1994","unstructured":"Hortin, G. L., Landt, M. & Powderly, W. G. Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin. Chem. 40, 785\u2013789 (1994).","journal-title":"Clin. Chem."},{"key":"35271_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/infdis\/jis205","volume":"205","author":"TL Stanley","year":"2012","unstructured":"Stanley, T. L. & Grinspoon, S. K. Body composition and metabolic changes in HIV-infected patients. J. Infect. Dis. 205, 383\u2013390 (2012).","journal-title":"J. Infect. Dis."},{"key":"35271_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s11306-011-0376-2","volume":"8","author":"A Williams","year":"2012","unstructured":"Williams, A., Koekemoer, G., Lindeque, Z., Reinecke, C. & Meyer, D. Qualitative serum organic acid profiles of HIV-infected individuals not on antiretroviral treatment. Metabolomics 8, 804\u2013818 (2012).","journal-title":"Metabolomics"},{"key":"35271_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0002-9343(89)90225-8","volume":"86","author":"C Grunfeld","year":"1989","unstructured":"Grunfeld, C. et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86, 27\u201331 (1989).","journal-title":"Am. J. Med."},{"issue":"12","key":"35271_CR7","doi-asserted-by":"publisher","first-page":"e0161920","DOI":"10.1371\/journal.pone.0161920","volume":"11","author":"Bruno Scarpelini","year":"2016","unstructured":"Scarpelini, B. et al. Plasma metabolomics biosignature according to HIV stage of infection, pace of disease progression, viremia level and immunological response to treatment. PLoS One 11 (2016).","journal-title":"PLOS ONE"},{"key":"35271_CR8","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1039\/C4MB00347K","volume":"10","author":"TR McKnight","year":"2014","unstructured":"McKnight, T. R. et al. A combined chemometric and quantitative NMR analysis of HIV\/AIDS serum discloses metabolic alterations associated with disease status. Mol. Biosyst. 10, 2889\u201397 (2014).","journal-title":"Mol. Biosyst."},{"issue":"5","key":"35271_CR9","doi-asserted-by":"publisher","first-page":"e64298","DOI":"10.1371\/journal.pone.0064298","volume":"8","author":"Saif Ullah Munshi","year":"2013","unstructured":"Munshi, S. U., Rewari, B. B., Bhavesh, N. S. & Jameel, S. Nuclear Magnetic Resonance Based Profiling of Biofluids Reveals Metabolic Dysregulation in HIV-Infected Persons and Those on Anti-Retroviral Therapy. PLoS One 8 (2013).","journal-title":"PLoS ONE"},{"key":"35271_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.virol.2011.04.007","volume":"415","author":"JA Hollenbaugh","year":"2011","unstructured":"Hollenbaugh, J. A., Munger, J. & Kim, B. Metabolite profiles of human immunodeficiency virus infected CD4+ T cells and macrophages using LC-MS\/MS analysis. Virology 415, 153\u20139 (2011).","journal-title":"Virology"},{"key":"35271_CR11","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1172\/JCI34138","volume":"118","author":"WR Wikoff","year":"2008","unstructured":"Wikoff, W. R., Pendyala, G., Siuzdak, G. & Fox, H. S. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J. Clin. Invest. 118, 2661\u20132669 (2008).","journal-title":"J. Clin. Invest."},{"key":"35271_CR12","first-page":"1","volume":"12","author":"M Hoffmann","year":"2016","unstructured":"Hoffmann, M. et al. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. PLoS Pathog. 12, 1\u201319 (2016).","journal-title":"PLoS Pathog."},{"key":"35271_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7861\/clinmedicine.11-6-571","volume":"11","author":"C Hogan","year":"2011","unstructured":"Hogan, C. & Wilkins, E. Neurological complications in HIV. Clin. Med. 11, 571\u20135 (2011).","journal-title":"Clin. Med."},{"key":"35271_CR14","doi-asserted-by":"publisher","first-page":"e0176686","DOI":"10.1371\/journal.pone.0176686","volume":"12","author":"J Gutierrez","year":"2017","unstructured":"Gutierrez, J., Albuquerque, A. L. A. & Falzon, L. HIV infection as vascular risk: A systematic review of the literature and meta-analysis. PLoS One 12, e0176686 (2017).","journal-title":"PLoS One"},{"key":"35271_CR15","doi-asserted-by":"publisher","first-page":"e2127","DOI":"10.1097\/MD.0000000000002127","volume":"94","author":"R Mohr","year":"2015","unstructured":"Mohr, R. et al. Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role? Medicine (Baltimore). 94, e2127 (2015).","journal-title":"Medicine (Baltimore)."},{"key":"35271_CR16","doi-asserted-by":"crossref","unstructured":"Van Wijk, J. P. H. & Cabezas, M. C. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: Effects of antiretroviral therapy and adipose tissue distribution. Int. J. Vasc. Med. 2012 (2012).","DOI":"10.1155\/2012\/201027"},{"key":"35271_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/dc07-2013","volume":"31","author":"S De Wit","year":"2008","unstructured":"De Wit, S. et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 31, 1224\u20139 (2008).","journal-title":"Diabetes Care"},{"key":"35271_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrneurol.2016.27","volume":"12","author":"D Saylor","year":"2016","unstructured":"Saylor, D. et al. HIV-associated neurocognitive disorder\u2013pathogenesis and prospects for treatment. Nat. Rev. Neurol. 12, 234\u201348 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"35271_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13365-010-0006-1","volume":"17","author":"RK Heaton","year":"2011","unstructured":"Heaton, R. K. et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J. Neurovirol. 17, 3\u201316 (2011).","journal-title":"J. Neurovirol."},{"key":"35271_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/infdis\/jiw096","volume":"214","author":"V Mave","year":"2016","unstructured":"Mave, V. et al. Inflammation and Change in Body Weight with Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-infected Adults. J. Infect. Dis. 214, 65\u201372 (2016).","journal-title":"J. Infect. Dis."},{"key":"35271_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0140435","volume":"10","author":"M Pogliaghi","year":"2015","unstructured":"Pogliaghi, M. et al. Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets. PLoS One 10, 1\u201315 (2015).","journal-title":"PLoS One"},{"key":"35271_CR22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1086\/656722","volume":"202","author":"SA Yukl","year":"2010","unstructured":"Yukl, S. A. et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J. Infect. Dis. 202, 1553\u201361 (2010).","journal-title":"J. Infect. Dis."},{"key":"35271_CR23","doi-asserted-by":"publisher","first-page":"e30881","DOI":"10.1371\/journal.pone.0030881","volume":"7","author":"A Kamat","year":"2012","unstructured":"Kamat, A. et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 7, e30881 (2012).","journal-title":"PLoS One"},{"key":"35271_CR24","doi-asserted-by":"publisher","first-page":"e114142","DOI":"10.1371\/journal.pone.0114142","volume":"9","author":"M Massanella","year":"2014","unstructured":"Massanella, M. et al. Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. PLoS One 9, e114142 (2014).","journal-title":"PLoS One"},{"key":"35271_CR25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/clinchem\/44.4.858","volume":"44","author":"M Huengsberg","year":"1998","unstructured":"Huengsberg, M. et al. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin. Chem. 44, 858\u2013862 (1998).","journal-title":"Clin. Chem."},{"key":"35271_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0078146","volume":"8","author":"MA Jenabian","year":"2013","unstructured":"Jenabian, M. A. et al. Distinct Tryptophan Catabolism and Th17\/Treg Balance in HIV Progressors and Elite Controllers. PLoS One 8, 1\u201313 (2013).","journal-title":"PLoS One"},{"key":"35271_CR27","first-page":"1045","volume":"74","author":"C Grunfeld","year":"1992","unstructured":"Grunfeld, C. et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74, 1045\u201352 (1992).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"35271_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1101029","volume":"188","author":"P Kalinski","year":"2012","unstructured":"Kalinski, P. Regulation of immune responses by prostaglandin E2. J. Immunol. (Baltimore, Md 1950) 188, 21\u201328 (2012).","journal-title":"J. Immunol. (Baltimore, Md 1950)"},{"issue":"3","key":"35271_CR29","doi-asserted-by":"publisher","first-page":"a006049","DOI":"10.1101\/cshperspect.a006049","volume":"4","author":"K. Newton","year":"2012","unstructured":"Newton, K. & Dixit, V. M. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4 (2012).","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"35271_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1399-0039.2005.00394.x","volume":"65","author":"H Harizi","year":"2005","unstructured":"Harizi, H. & Gualde, N. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens 65, 507\u2013514 (2005).","journal-title":"Tissue Antigens"},{"key":"35271_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11904-010-0066-0","volume":"8","author":"A Khaitan","year":"2011","unstructured":"Khaitan, A. & Unutmaz, D. Revisiting immune exhaustion during HIVinfection. Curr. HIV\/AIDS Rep. 8, 4\u201311 (2011).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"35271_CR32","first-page":"3","volume":"9","author":"J Chen","year":"2014","unstructured":"Chen, J. et al. Anti-Retroviral Therapy Decreases but Does Not Normalize Indoleamine 2. 3-Dioxygenase Activity in HIV- Infected Patients. 9, 3\u201310 (2014).","journal-title":"3-Dioxygenase Activity in HIV- Infected Patients."},{"key":"35271_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2174\/157016206778559993","volume":"4","author":"D Torre","year":"2006","unstructured":"Torre, D. & Pugliese, A. Interleukin-18: a proinflammatory cytokine in HIV-1 infection. Curr. HIV Res. 4, 423\u201330 (2006).","journal-title":"Curr. HIV Res."},{"key":"35271_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2011.03.015","volume":"217","author":"BJMH Jefferis","year":"2011","unstructured":"Jefferis, B. J. M. H. et al. Interleukin 18 and coronary heart disease: Prospective study and systematic review. Atherosclerosis 217, 227\u2013233 (2011).","journal-title":"Atherosclerosis"},{"key":"35271_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1475-2840-9-11","volume":"9","author":"M Tr\u00f8seid","year":"2010","unstructured":"Tr\u00f8seid, M., Seljeflot, I. & Arnesen, H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc. Diabetol. 9, 11 (2010).","journal-title":"Cardiovasc. Diabetol."},{"key":"35271_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-S1-O33","volume":"13","author":"R Mih\u0103ilescu","year":"2013","unstructured":"Mih\u0103ilescu, R. et al. Correlation between inflammatory biomarkers and metabolic disorders in HIV infected patients undergoing antiretroviral therapy. BMC Infect. Dis. 13, O33 (2013).","journal-title":"BMC Infect. Dis."},{"key":"35271_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.spen.2008.05.007","volume":"15","author":"GM Enns","year":"2008","unstructured":"Enns, G. M. Neurologic damage and neurocognitive dysfunction in urea cycle disorders. Semin. Pediatr. Neurol. 15, 132\u20139 (2008).","journal-title":"Semin. Pediatr. Neurol."},{"key":"35271_CR38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","volume":"173","author":"MS Freiberg","year":"2013","unstructured":"Freiberg, M. S. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 173, 614\u201322 (2013).","journal-title":"JAMA Intern. Med."},{"key":"35271_CR39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","volume":"17","author":"N Friis-M\u00f8ller","year":"2003","unstructured":"Friis-M\u00f8ller, N. et al. Cardiovascular disease risk factors in HIV patients \u2013 association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179\u20131193 (2003).","journal-title":"AIDS"},{"issue":"Suppl","key":"35271_CR40","doi-asserted-by":"publisher","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","volume":"50","author":"EM Smyth","year":"2009","unstructured":"Smyth, E. M., Grosser, T., Wang, M., Yu, Y. & FitzGerald, G. A. Prostanoids in health and disease. J. Lipid Res. 50(Suppl), S423\u20138 (2009).","journal-title":"J. Lipid Res."},{"key":"35271_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1073\/pnas.96.1.272","volume":"96","author":"BF McAdam","year":"1999","unstructured":"McAdam, B. F. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. 96, 272\u2013277 (1999).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"35271_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/01.RES.0000139436.89654.c8","volume":"95","author":"J Seubert","year":"2004","unstructured":"Seubert, J. et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K\u2009+\u2009channels and p42\/p44 MAPK pathway. Circ. Res. 95, 506\u2013514 (2004).","journal-title":"Circ. Res."},{"key":"35271_CR43","first-page":"1","volume":"9","author":"G Wong","year":"2014","unstructured":"Wong, G. et al. Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction. PLoS One 9, 1\u20137 (2014).","journal-title":"PLoS One"},{"key":"35271_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.aca.2015.12.009","volume":"908","author":"M Karimpour","year":"2016","unstructured":"Karimpour, M. et al. Postprandial metabolomics: A pilot mass spectrometry and NMR study of the human plasma metabolome in response to a challenge meal. Anal. Chim. Acta 908, 121\u201331 (2016).","journal-title":"Anal. Chim. Acta"},{"key":"35271_CR45","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/archinternmed.2012.3708","volume":"172","author":"D Sidhu","year":"2012","unstructured":"Sidhu, D. & Naugler, C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch. Intern. Med. 172, 1707\u201310 (2012).","journal-title":"Arch. Intern. Med."},{"key":"35271_CR46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1542\/peds.2011-0844","volume":"128","author":"MJ Steiner","year":"2011","unstructured":"Steiner, M. J., Skinner, A. C. & Perrin, E. M. Fasting might not be necessary before lipid screening: a nationally representative cross-sectional study. Pediatrics 128, 463\u201370 (2011).","journal-title":"Pediatrics"},{"key":"35271_CR47","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1086\/644769","volume":"49","author":"A Martin","year":"2009","unstructured":"Martin, A. et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin. Infect. Dis. 49, 1591\u2013601 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"35271_CR48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.mrrev.2007.12.001","volume":"658","author":"OA Olivero","year":"2008","unstructured":"Olivero, O. A. Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy. Mutat. Res. Mutat. Res. 658, 184\u2013190 (2008).","journal-title":"Mutat. Res. Mutat. Res."},{"key":"35271_CR49","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1021\/pr800373m","volume":"7","author":"C Hu","year":"2008","unstructured":"Hu, C. et al. RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. J. Proteome Res. 7, 4982\u201391 (2008).","journal-title":"J. Proteome Res."},{"key":"35271_CR50","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11306-011-0306-3","volume":"8","author":"MJ Noga","year":"2012","unstructured":"Noga, M. J. et al. Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 8, 253\u2013263 (2012).","journal-title":"Metabolomics"},{"key":"35271_CR51","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00216-012-6226-x","volume":"404","author":"K Strassburg","year":"2012","unstructured":"Strassburg, K. et al. Quantitative profiling of oxylipins through comprehensive LC-MS\/MS analysis: application in cardiac surgery. Anal. Bioanal. Chem. 404, 1413\u201326 (2012).","journal-title":"Anal. Bioanal. Chem."},{"key":"35271_CR52","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00216-018-0912-2","volume":"410","author":"JC Schoeman","year":"2018","unstructured":"Schoeman, J. C. et al. Development and application of a UHPLC-MS\/MS metabolomics based comprehensive systemic and tissue-specific screening method for inflammatory, oxidative and nitrosative stress. Anal. Bioanal. Chem. 410, 2551\u20132568 (2018).","journal-title":"Anal. Bioanal. Chem."},{"key":"35271_CR53","doi-asserted-by":"publisher","first-page":"12254","DOI":"10.1128\/JVI.00775-14","volume":"88","author":"J Hou","year":"2014","unstructured":"Hou, J. et al. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection. J. Virol. 88, 12254\u201312264 (2014).","journal-title":"J. Virol."},{"key":"35271_CR54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/infdis\/jiv391","volume":"213","author":"M Spaan","year":"2016","unstructured":"Spaan, M. et al. Immunological analysis during interferon-free therapy for chronic Hepatitis C virus infection reveals modulation of the natural killer cell compartment. J. Infect. Dis. 213, 216\u2013223 (2016).","journal-title":"J. Infect. Dis."},{"key":"35271_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hep.27805","volume":"62","author":"T Vanwolleghem","year":"2015","unstructured":"Vanwolleghem, T. et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology 62, 87\u2013100 (2015).","journal-title":"Hepatology"},{"key":"35271_CR56","doi-asserted-by":"publisher","first-page":"W251","DOI":"10.1093\/nar\/gkv380","volume":"43","author":"J Xia","year":"2015","unstructured":"Xia, J., Sinelnikov, I. V., Han, B. & Wishart, D. S. MetaboAnalyst 3.0\u2014making metabolomics more meaningful. Nucleic Acids Res. 43, W251\u2013W257 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35271-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:48:15Z","timestamp":1671623295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35271-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"6 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16947"}}